Renal transplantation across HLA and ABO antibody barriers: Integrating paired donation into desensitization protocols

American Journal of Transplantation

Volumn 10, Issue 3, 2010, Pages 449-457

  Montgomery, Robert A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ABO incompatibility; Allosensitization; Anitbody mediated rejection; Desensitization; Intravenous immunoglobulin; Kidney exchanges; Kidney transplantation; Plasmapheresis; Positive crossmatch

Indexed keywords

BORTEZOMIB; CD20 ANTIBODY; ECULIZUMAB; HLA ANTIBODY; IMMUNOGLOBULIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; STEROID; TACROLIMUS; BLOOD GROUP ABO SYSTEM; HLA ANTIGEN;

BLOOD GROUP ABO INCOMPATIBILITY; BLOOD GROUP ABO SYSTEM; CLINICAL TRIAL; CONFERENCE PAPER; DESENSITIZATION; DRUG EFFICACY; DRUG MEGADOSE; GRAFT SURVIVAL; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; LOW DRUG DOSE; PHENOTYPE; PLASMAPHERESIS; PRIORITY JOURNAL; SPLENECTOMY; TREATMENT DURATION; B LYMPHOCYTE; DONOR; HISTOCOMPATIBILITY TEST; HOSPITAL ADMISSION; KIDNEY; METABOLISM; PATHOLOGY; PROCEDURES; TRANSPLANTATION; TREATMENT OUTCOME;

ABO BLOOD-GROUP SYSTEM; B-LYMPHOCYTES; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; KIDNEY; KIDNEY TRANSPLANTATION; LIVING DONORS; PHENOTYPE; PLASMAPHERESIS; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS; TREATMENT OUTCOME; WAITING LISTS;

EID: 76949097232     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.03001.x     Document Type: Conference Paper

References (32)

1. Segev DL, Gentry SE, Warren DS, Reeb B, Montgomery RA. Kidney paired donation and optimizing the use of live donor organs. JAMA 2005 293 : 1883 1890.
2. Gentry SE, Segev DL, Montgomery RA. A comparison of populations served by kidney paired donation and list paired donation. Am J Transplant 2005 5 : 1914 1921.
3. Glotz D, Antoine C, Julia P et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002 2 : 758 760.
4. Tyan DB, Li VA, Czer L, Trento A, Jordan SC. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994 57 : 553 562.
5. Montgomery RA, Zachary AA, Racusen LC et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000 70 : 887 895.
6. Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: Contraindication vs. risk. Am J Transplant 2003 3 : 1488 1500.
7. Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch: A single center's perspective. Pediatr Transplant 2004 8 : 535 542.
8. Jordan SC, Tyan D, Stablein D et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IG02 trial. J Am Soc Nephrol 2004 15 : 3256 3262.
9. Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006 6 : 346 351.
10. Vo AA, Lukovsky M, Toyoda M et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008 359 : 242 251.
11. Tyden G, Kumlien G, Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation 2003 76 : 730 731.
12. Locke JE, Zachary AA, Haas M et al. The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant 2007 7 : 842 846.
13. Montgomery RA, Locke JE, King KE et al. ABO incompatible renal transplantation: A paradigm ready for broad implementation. Transplantation 2009 87 : 1246 1255.
14. Everly MJ, Everly JJ, Susskind B et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008 86 : 1754 1761.
15. Locke JE, Magro CM, Singer AL et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009 9 : 231 235.
16. Gloor JM, DeGoey SR, Pineda AA et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003 3 : 1017 1023.
17. Zachary AA, Montgomery RA, Ratner LE et al. Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation 2003 76 : 1519 1525.
18. Gloor JM, DeGoey S, Ploeger N et al. Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation. Transplantation 2004 78 : 221 227.
19. Gloor JM, Cosio FG, Rea DJ et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006 6 : 1841 1847.
20. Ross LF, Rubin DT, Siegler M et al. Ethics of a paired-kidney-exchange program. N Engl J Med 1997 336 : 1752 1755.
21. Montgomery RA, Zachary AA, Ratner LE et al. Clinical results from transplanting incompatible live kidney donor/recipient pairs using kidney paired donation. JAMA 2005 294 : 1655 1663.
22. Gentry SE, Segev DL, Simmerling M, Montgomery RA. Expanding kidney paired donation through participation by compatible pairs. Am J Transplant 2007 7 : 2361 2370.
23. de Klerk M, Keizer KM, Claas FH et al. The Dutch national living donor kidney exchange program. Am J Transplant 2005 5 : 2302 2305. (Pubitemid 41648480)
24. Delmonico FL, Morrissey PE, Lipkowitz GS et al. Donor kidney exchanges. Am J Transplant 2004 4 : 1628 1634.
25. Zenios SA, Woodle ES, Ross LF. Primum non nocere: Avoiding harm to vulnerable wait list candidates in an indirect kidney exchange. Transplantation 2001 72 : 648 654.
26. Adams PL, Cohen DJ, Danovitch GM et al. The nondirected live-kidney donor: Ethical considerations and practice guidelines: A National Conference Report. Transplantation 2002 74 : 582 589.
27. Montgomery RA, Gentry SE, Marks WH et al. Domino paired kidney donation: A strategy to make best use of live non-directed donation. Lancet 2006 368 : 419 421.
28. Montgomery RA, Katznelson S, Bry WI et al. Successful three-way kidney paired donation with cross-country live donor allograft transport. Am J Transplant 2008 8 : 2163 2168.
29. Rees MA, Kopke JE, Pelletier RP et al. A Nonsimultaneous, Extended, Altruistic-Donor Chain. N Engl J Med 2009 360 : 1096 1101.
30. Gentry SE, Montgomery RA, Swihart BJ, Segev DL. The roles of dominos and never-ending altruistic donor chains in kidney paired donation. Am J Transplant 2009 9 : 1330 1336.
31. Burns JM, Cornell LD, Perry DK et al. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am J Transplant 2008 8 : 2684 2694.
32. Shimmura H, Tanabe K, Ishida H et al. Lack of correlation between results of ABO-incompatible living kidney transplantation and anti-ABO blood type antibody titers under our current immunosuppression. Transplantation 2005 80 : 985 988.